Publicaciones en las que colabora con MIGUEL ANGEL SANZ ALONSO (17)

2022

  1. Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia

    Bone Marrow Transplantation, Vol. 57, Núm. 9, pp. 1389-1398

2021

  1. Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-vs-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation

    European Journal of Haematology, Vol. 106, Núm. 1, pp. 114-125

2020

  1. Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies

    Biology of Blood and Marrow Transplantation, Vol. 26, Núm. 2, pp. 358-366

  2. Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors

    Bone Marrow Transplantation, Vol. 55, Núm. 11, pp. 2147-2159

2017

  1. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis

    Neurological Sciences, Vol. 38, Núm. 7, pp. 1213-1221

  2. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

  3. Single umbilical cord blood with or without CD341 cells from a third-party donor in adults with leukemia

    Blood Advances, Vol. 1, Núm. 15, pp. 1047-1055

2016

  1. Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico

    Biology of Blood and Marrow Transplantation, Vol. 22, Núm. 3, pp. 584-588

  2. Umbilical cord blood transplantation in adults with advanced hodgkin's disease: High incidence of post-transplant lymphoproliferative disease

    European Journal of Haematology, Vol. 96, Núm. 2, pp. 128-135

2013

  1. Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach

    Biology of Blood and Marrow Transplantation, Vol. 19, Núm. 1, pp. 69-74

2012

  1. Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen

    Bone Marrow Transplantation, Vol. 47, Núm. 10, pp. 1287-1293

2010

  1. Unrelated Transplantation for Poor-Prognosis Adult Acute Lymphoblastic Leukemia: Long-Term Outcome Analysis and Study of the Impact of Hematopoietic Graft Source

    Biology of Blood and Marrow Transplantation, Vol. 16, Núm. 7, pp. 957-966

2009

  1. Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: A phase II trial

    Leukemia and Lymphoma, Vol. 50, Núm. 2, pp. 216-222

2003

  1. Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation

    Experimental Hematology

2002

  1. Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34 + selected blood cells from HLA-identical siblings

    Blood, Vol. 100, Núm. 2, pp. 724-727

2001

  1. The number of donor CD3+ cells is the most important factor for graft failure after allogeneic transplantation of CD34+ selected cells from peripheral blood from HLA-identical siblings

    Blood, Vol. 97, Núm. 2, pp. 383-387

1999

  1. Administration of recombinant human granulocyte colony-stimulating factor to normal donors: Results of the Spanish National Donor Registry

    Bone Marrow Transplantation, Vol. 24, Núm. 7, pp. 723-728